News Releases
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
June 30, 2026 - New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license.
Light-activated small molecule could transform eye infection treatment
April 22, 2026 - Many contact lens users occasionally fall asleep with their lenses in. However, this can cause dry and irritated eyes and blurry vision, which may be a sign of a serious infection.
Authority Magazine Interview
May 7, 2025 – Authority Magazine launched a new interview series highlighting tech leaders creating meaningful social and environmental change. As part of “Technology Making An Important Positive Social Impact,” Edward Pershing, Chairman of VisiRose, Inc. and CEO of Provectus Biopharmaceuticals, was interviewed about his company’s impact.
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs
January 14, 2025 – Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc., Provectus’s Founded Entity that is developing novel ocular therapeutics.
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
January 14, 2025 — VisiRose Inc. today announced the closing of a $3 million seed financing round.
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
Dec 11, 2024 - Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded Entity.
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Dec 10, 2024 - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI).